Physician profile
Nihit Shah
NPI 1639539109
$1,794.03
in general payments reported to CMS, 2019-2025
21 companies · $614 in 2025
The $614 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.57 · 2021: $22.59 · 2022: $43.25 · 2023: $417 · 2024: $613 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.87 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $266.63 | 2023-2025 | |
| Abbvie INC. | $264.85 | 2019-2025 | Linzess, Creon, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $205.77 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $90.83 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $66.40 | 2023-2024 | Dupixent |
| Boston Scientific Corporation | $62.80 | 2021-2024 | Watchman |
| Pfizer INC. | $60.40 | 2023-2025 | |
| Qol Medical, LLC | $48.12 | 2023-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $46.44 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $44.92 | 2025 | Ibsrela |
| Covidien LP | $40.90 | 2019 | |
| Celgene Corporation | $32.30 | 2024 | Zeposia |
| Aimmune Therapeutics, INC. | $32.29 | 2024 | |
| Lilly USA, LLC | $31.88 | 2024 | Omvoh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $18.34 | 2025 | Vegzelma |
| Ge Healthcare | $16.82 | 2025 | |
| Ironwood Pharmaceuticals, INC | $16.38 | 2023 | Linzess |
| Madrigal Pharmaceuticals | $14.50 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $11.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nihit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.